Andrea L. Kasinski

Aberrant regulation and function of microRNAs in cancer.

A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer.

RNA-guided CRISPR-Cas technologies for genome-scale investigation of disease processes.

MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy.

Targeting adhesion signaling in mutant lung adenocarcinoma.

Sulforhodamine B (SRB) Assay in Cell Culture to Investigate Cell Proliferation.

FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer.

Animal Models to Study MicroRNA Function.

No vehicle, no problem.

MicroRNA-223 Suppresses the Canonical NF-κB Pathway in Basal Keratinocytes to Dampen Neutrophilic Inflammation.

New Mechanism for Release of Endosomal Contents: Osmotic Lysis via Nigericin-Mediated K/H Exchange.

Enhancing MicroRNA Activity through Increased Endosomal Release Mediated by Nigericin.

Identification and validation of microRNAs that synergize with miR-34a - a basis for combinatorial microRNA therapeutics.

Combatting PDAC with two tumor-targeting small RNAs.

Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer.

InVivo Cancer-Based Functional Genomics.

MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic.

Ligand-mediated delivery of RNAi-based therapeutics for the treatment of oncological diseases.

Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.

Author Correction: Extracellular vesicles released by non-small cell lung cancer cells drive invasion and permeability in non-tumorigenic lung epithelial cells.

Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET.

In-Cell Western Protocol for Semi-High-Throughput Screening of Single Clones.

Emerging diversity in extracellular vesicles and their roles in cancer.

A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.

Histone 4 lysine 20 tri-methylation: a key epigenetic regulator in chromatin structure and disease.